Navigation Links
DURECT Corporation Invites You to Join its Third Quarter 2011 Earnings Conference Call
Date:10/26/2011

CUPERTINO, Calif., Oct. 26, 2011 /PRNewswire/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) third quarter 2011 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Thursday, November 3, 2011 at 4:30 pm Eastern Time (1:30 pm Pacific Time).

(Logo:  http://photos.prnewswire.com/prnh/20020717/DRRXLOGO)

A live audio webcast of the presentation will be available by accessing DURECT's homepage at http://www.durect.com and clicking "Investor Relations."  If you are unable to participate during the live webcast, the call will be archived on DURECT's website under Audio Archive in the "Investor Relations" section.

About DURECT Corporation

DURECT is a specialty pharmaceutical company developing innovative drugs for pain and other chronic diseases, with late-stage development programs including REMOXY®, POSIDUR™, ELADUR®, and TRANSDUR®-Sufentanil.  DURECT's proprietary oral, transdermal and injectable depot delivery technologies may enable new indications and superior clinical/commercial attributes such as abuse deterrence, improved convenience, compliance, efficacy and safety for small molecule and biologic drugs.  For more information, please visit www.durect.com.

NOTE: POSIDUR™, SABER™, ORADUR®, TRANSDUR®, and ELADUR® are trademarks of DURECT Corporation. Other referenced trademarks belong to their respective owners.  REMOXY, POSIDUR, ELADUR and TRANSDUR-Sufentanil are drug candidates under development and have not been approved for commercialization by the U.S. Food and Drug Administration or other health authorities.


'/>"/>
SOURCE DURECT Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. DURECT Completes Enrollment in Pivotal U.S. Phase III Trial for POSIDUR® (BESST)
2. DURECT Corporation to Participate in Upcoming Healthcare Conferences
3. DURECT Corporation Announces Second Quarter 2011 Financial Results and Update of Programs
4. DURECT Corporation Invites You to Join its Second Quarter 2011 Earnings Conference Call
5. DURECT to Present at the Jefferies Healthcare Conference
6. DURECT Announces Resignation of Chief Medical Officer
7. DURECT to Present at the UBS Global Specialty Pharmaceuticals Conference
8. DURECT Announces ELADUR® (TRANSDUR®-Bupivacaine) Phase II Study Results in Chronic Low Back Pain
9. DURECT to Present at Cowen and Company Health Care Conference
10. DURECT Corporation Invites You to Join its Fourth Quarter 2010 Earnings Conference Call
11. DURECT Reports Data From European Phase IIb Shoulder Study of POSIDUR™ (SABER™-Bupivacaine) and Amendment of the Nycomed Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... PALO ALTO, Calif. , Aug. 1, 2014 ... today announced a partnership to expand awareness of proper ... the CFChef Shares program. CFChef Shares will run from ... AbbVie,s CFChef program – an online resource for CF ... a healthy diet by submitting recipes to the ...
(Date:8/1/2014)... Mass. , Aug. 1, 2014  NxStage Medical, Inc. ... dialysis products, today announced that Jeffrey H. Burbank , ... Officer, will present at the 34 th Annual Canaccord ... Boston, MA , on Wednesday, August 13 th ... will be made available at http://ir.nxstage.com/ .  ...
(Date:8/1/2014)... Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced ... report its second quarter 2014 financial results on Monday, ... J. Joseph Kim and CFO Peter ... corporate update, and participate in a live Q&A with ... VGX-3100, Inovio,s immune therapy targeting pre-cancers and cancers associated ...
Breaking Medicine Technology:AbbVie and Cystic Fibrosis Research, Inc. (CFRI) Team Up to Raise Awareness of the Nutritional Needs of CF Patients through the CFChef Shares Program 2AbbVie and Cystic Fibrosis Research, Inc. (CFRI) Team Up to Raise Awareness of the Nutritional Needs of CF Patients through the CFChef Shares Program 3NxStage to Present at the 34th Annual Canaccord Genuity Growth Conference 2Inovio Pharmaceuticals to Host Second Quarter 2014 Financial Results Call on August 11, 2014 2Inovio Pharmaceuticals to Host Second Quarter 2014 Financial Results Call on August 11, 2014 3
(Date:8/1/2014)... Gerontological Society of America (GSA) ... field of aging has chosen Madonna Harrington ... PhD, of the University of Luxembourg; and Philipp ... The London School of Economics and Political Science ... Innovative Publication Awards. , These distinguished honors recognize ...
(Date:8/1/2014)... 2014 Lifeinsurancenomedicalexam.info has released a ... for clients who have high cholesterol levels. , ... and qualify for no medical exam life insurance. These ... background medical check-ups. , Since there are no medical ... will qualify in just a few minutes. However, this ...
(Date:8/1/2014)... August 01, 2014 Home Care Assistance ... seniors, is honored to be recognized as a 2014 Best ... given to home care providers who rank in the top ... on monthly satisfaction interviews conducted by Home Care Pulse. , ... home care businesses, the best of the best!” says Home ...
(Date:8/1/2014)... aesthetic injectable procedures have grown in popularity as more ... As Botulinum toxin generally known as BOTOX ... health professionals have emerged to perform procedures utilizing this ... Spinelli, MD from the Division of Plastic Surgery Presbyterian ... from Columbia University in New York have assessed the ...
(Date:8/1/2014)... CapsCanada, a leading provider of ... new K-CAPS® (HPMC capsules) manufacturing facility in Lakeshore, ... last year while experiencing growing global demand for ... “KCAPS® are currently sold in more than 60 ... to other HPMC capsules, K-CAPS® have exceptional appearance ...
Breaking Medicine News(10 mins):Health News:Harrington Meyer, Leist, Hessel, Avendano to receive GSA's 2014 Kalish awards 2Health News:No Exam Life Insurance - Coverage for Clients Who Have High Cholesterol 2Health News:Cincinnati Senior Care Company Receives 2014 Best of Home Care® Employer of Choice Award 2Health News:Plastic surgeons or nurses: Who are the better injectors? 2
... focused on the use of cholesterol-lowering drugs also ... and C-reactive protein levels. C-reactive protein is a ... inflammation in the arteries. One study shows C-reactive ... cardiovascular risk.,Researchers focused on whether the lower low-density ...
... heart's own can, such as raising the heart rate when ... hill but researchers say a pacemaker created by // stem ... shown that genetically engineered heart cells from human embryonic stem ... to a new study. Researchers injected clusters of human beating ...
... body’s immune system and help protect the body against ... shows promising treatment for acute myelogenous leukemia // ... from a patient’s family member. Researchers say this ... cancer of the bone marrow that has become resistant ...
... unexpected structural differences in the brains of cocaine addicts. ... brain structure // of 27 cocaine addicts to that ... ,Results showed the amygdala -- a key structure in ... brain's reward processing system -- is smaller in cocaine ...
... more important factor associated with childhood allergies and asthma than ... to a new study . // ,The study ... a sample of their cord blood serum taken at birth ... showing a sensitization to certain allergens.The children were assessed at ...
... Epilepsy is a disorder caused by abnormal surges in the ... is found to affect more than 2 million people worldwide. ... by just taking medications. // ,Researchers now say that ... effective surgery is compared to drug therapy when treating those ...
Cached Medicine News:
The AIA-600 II has become the new standard in benchtop immunoassay analyzers....
... The ACON PSA Semi-Quantitative Prostate Specific ... Blood/Serum/Plasma) are lateral flow tests in strip ... of Prostate Specific Antigen (PSA). The tests ... ng/mL cut-off values, and all come with ...
... Assess Functional Vision, Quality of Vision ... controls both target illumination and glare ... testing results. Day/Night testing with/without glare ... Standards and all ANSI standards. All ...
... is Recognized as a Valuable Tool ... by Early Eye Disease. Near Test ... 7 in (12.7cm x 17.78cm) Can ... Refractor,Distance Test F.A.C.T. 201: Size ...
Medicine Products: